pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
VX-661 Plus Ivacaftor Combination
Phase 3 · small molecule · Cystic Fibrosis
VX-661 Plus Ivacaftor Combination for Cystic Fibrosis is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Australia) Pty. with 2 ClinicalTrials.gov record(s).
Internal code VX14-661-106
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vertex Pharmaceuticals (Australia) Pty.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Cystic Fibrosis
- Status
- completed
- Trials
- 2